Eyes On the Prize: From Sicilian Roots to FDA Approval
Historically, SIFI has been a modest local player focused on ophthalmic products, but in recent years the company has set some ambitious goals for itself—becoming a leading force in European…
Advanced Life Science in Italy (ALISEI) is a technology cluster set up to encourage interaction in the health sector – a strategic area for research and innovation in Italy – between research institutions, business and public sector bodies.
The ALISEI cluster works as a facilitator and accelerator in the complex process of transferring knowledge and technologies from multidisciplinary research to the pharmaceutical and biomedical industry, leveraging on public sector and private research laboratories, advanced manufacturing facilities and high value-added services.
ALISEI makes it possible to direct and share Italian and European best practices and engages with regional, national and international policy makers as well as with public and private stakeholders in the life science sector.
Contact
Historically, SIFI has been a modest local player focused on ophthalmic products, but in recent years the company has set some ambitious goals for itself—becoming a leading force in European…
Seasoned executive Pierluigi Antonelli went from a career in big pharma to Angelini Pharma, a midsized Italian company that has been undergoing major transformation. He shares the motivation behind the…
Collectively representing almost 400 companies operating in Italy, Farmindustria, Egualia (formerly Assogenerici) and Assobiotec respectively promote the interests of innovative pharmaceutical companies—both foreign and Italian-owned— the generics, biosimilars and value-added…
As the European Union’s largest beneficiary of the Next Generation EU (NGEU) package, aimed at boosting the EU’s economy following the COVID-19 pandemic, Italy will receive some EUR 235 billion…
While Italy’s biotech landscape is generally held to be somewhat immature in comparison to more established markets such as Germany, France or the UK, that does not imply a deficit…
Dr Nicola Normanno, the Director of the Translational Research Department of one of Italy’s national cancer institutes, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, and president of the Italian Cancer…
Tiziana Mele, managing director of Lundbeck Italia, explains the impact of COVID on mental health care from the perspective of a company dedicated to brain health, outlines the Italian operation…
Guerbet’s Alessandro Bocci – General Manager Italy & Iberia – describes the nearly 100-year-old company’s firm position in the field of contrast media for radiology and its plans for developing…
Medtronic’s Michele Perrino, Regional VP North Western Europe & Italy, Cardiovascular Commercial Partnership WE, outlines the company’s change in positioning from medtech to healthcare technology and the central role of…
Giuseppe Maduri, Chairman, Managing Director, General Manager Italy, Greece, Cyprus, Malta at Astellas Pharma explains the Japanese company’s focus on unmet needs and how Italy, one of its top European…
Chairman & Managing Director of B. Braun Milano, Klaus D. Pannes, shares the importance of the German medtech’s Italian affiliate, one of its top ten by third-party sales, which is…
Paivi Kerkola, Country Manager, Managing Director and President of Pfizer Italy, speaks about the peculiarities of the Italian market from a northern European perspective, her priorities, and the impact of…
See our Cookie Privacy Policy Here
